Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis

Wei Wang¹, Zaoxiu Hu², Jie Zhao¹, Yunchao Huang¹, Sunyin Rao¹, Jichen Yang¹, Shouyong Xiao¹, Run Cao¹ and Lianhua Ye¹*

Abstract

Objective: It has been confirmed that the micropapillary (MP) pattern is a poor prognostic factor after resection of lung adenocarcinoma (ADC), but the proportion of the MP component as a prognostic criterion is still controversial. Hence, a meta-analysis was performed to evaluate whether the presence of an MP component has equal prognostic power as the MP predominant subtype.

Methods: Literature retrieval was performed in the MEDLINE, EMBASE, and Cochrane databases until December 23, 2019. Eligible studies were selected based on the inclusion and exclusion criteria. The included studies were divided into two subgroups, the MP component subgroup and the MP predominant subgroup, according to the proportion of the MP pattern to analyse the effect of this pattern on disease-free survival (DFS) and overall survival (OS). The hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study. Review Manager 5.3 was used for statistical analyses.

Results: Finally, 10 studies, including a total of 4934 lung ADC patients, were included in this meta-analysis. Our results indicated a significantly worse pooled DFS (HR 1.62, 95% CI 1.20–2.21) and OS (HR 1.53, 95% CI 1.19–1.96) in the subgroup of MP predominant subtype patients. The pooled DFS (HR 1.80, 95% CI 1.45–2.85) and OS (HR 2.26, 95% CI 1.46–3.52) were also poor in the subgroup of patients with the presence of an MP component.

Conclusions: Both the presence of an MP component and the MP predominant subtype are related to poor DFS and OS after lung ADC resection and represent adverse prognostic factor for lung ADC patients. However, there are some limitations in this meta-analysis, and quantitative stratification based on the proportion of the MP component is needed to explore its effect on prognosis of lung ADC patients in the future.

Keywords: Presence of micropapillary component, Micropapillary predominant subtype, Lung adenocarcinoma, Prognosis, Meta-analysis

*Correspondence: lhye1204@aliyun.com

¹Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No. 519 Kunzhou Road, Xishan District, Kunming City, Yunnan Province, China

Full list of author information is available at the end of the article
**Introduction**

Primary bronchial lung cancer is one of the most malignant tumours with the highest morbidity and mortality in China and the world, seriously endangering human health [1]. Adenocarcinoma (ADC) is the most common histological type of lung cancer, accounting for almost 50% of all lung cancers [2]. The International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society (IASLC/ATS/ERS) proposed a new histological classification method for lung ADC in 2011 [3]. According to the recommendations of the new classification, the 5 main growth patterns (lepidic, acinar, papillary, micropapillary and solid) of invasive lung ADC should be recorded in 5% increments, and the pattern with the highest proportion determines the predominant subtype [4].

Studies have shown that the new classification is an independent predictor of disease-free survival (DFS) and overall survival (OS) in lung ADC [5–7]. In recent years, many studies have reported the poor prognosis of lung ADC with the micropapillary (MP)-predominant subtype [8, 9]. In addition, studies have shown that the MP predominant subtype of lung ADC is closely related to lymph node metastasis, vascular tumour thrombosis, visceral pleural invasion, and spread through air spaces (STAS) [10–12]. Two studies showed that the presence of an MP component does not suggest a poor prognosis for lung ADC [13, 14]. The proportion of the MP component as a prognostic criterion is still controversial. It is uncertain whether the presence of an MP component has equal prognostic power as the MP predominant subtype.

The aim of this study was to review the available data and conduct a meta-analysis, dividing the studies into two subgroups, the MP component subgroup and the MP predominant subgroup, according to the proportion of the MP pattern to clarify the effect of this pattern on the prognosis of lung ADC after resection.

**Methods**

**Eligibility criteria**

Eligible studies included observational studies assessing the significance of the lung ADC subtype for prognosis. The selected studies met the following criteria: (1) the research subjects were patients with confirmed lung ADC after surgical resection as evaluated by the comprehensive and detailed histological diagnostic model according to the new IASLC/ATS/ERS classification; (2) the MP pattern was defined as MP predominant or containing an MP component; (3) DFS and/or OS should be evaluated in the study; and (4) the hazard ratio (HR) of DFS and/or OS was obtained through multivariate Cox regression analysis. Studies meeting the following criteria were excluded: (1) editorials, letters, reviews, conference abstracts, and case reports; (2) studies published in a non-English language; (3) incomplete information or the HR and 95% CI could not be calculated; (4) the patients received neoadjuvant therapy before surgery; and (5) studies with an unclear definition of the MP pattern or inconsistent standards defining the presence of an MP component.

**Search strategy**

The included studies were identified through an electronic search of the MEDLINE, EMBASE, and Cochrane databases, and the deadline was December 23, 2019. In addition, other related studies were obtained by scanning the reference lists of the included studies. Search terms were combined as follows: (micropapillary predominant OR micropapillary component OR micropapillary pattern OR micropapillary subtype OR micropapillary minor) AND (resect OR resection OR operate OR operation OR lobectomy OR limited resection) AND (cancer OR carcinoma OR tumour OR neoplasm) AND (lung OR pulmonary) AND (survival OR prognosis).

Two authors (WW and ZH) independently browsed the titles and abstracts of all the studies identified by the electronic searching and then acquired the full articles for all potentially relevant studies. Next, the full texts of these potentially relevant studies were read through by the previous two authors to select studies that met the inclusion criteria. In the censoring process, any inconsistencies between the two authors needed to be discussed with the senior author (LY).

**Data extraction and quality assessment**

Data extraction was performed independently by the two authors (JZ and SR). The information needed to be extracted included: (1) first author, year of publication, study region, type of study, starting and ending years; (2) total number of patients, MP pattern definition, number of MP patients, Tumor Node Metastasis (TNM) staging distribution, surgical approach, and median follow-up time; and (3) the HR of DFS and/or OS and 95% CI.

The quality of included studies was evaluated independently by the two authors (JY and SX) after reading the full texts, and the Quality In Prognosis Studies (QUIPS) tool [15] was used to assess the risk of bias. Each domain was evaluated as having a low, medium or high bias risk from the six aspects including the research object, the study of lost follow-up, the measurement of prognostic factors, the measurement of outcomes, the confounding of research, and the statistical analysis of data and reporting. Any inconsistencies between the two authors were discussed with the senior author (YH).
Data analysis
The Review Manager 5.3 software (Rev-Man, version 5.3, Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2014) was used in this study for meta-analysis of survival data. According to the HR and 95% CI reported in the included studies, the Ln (HR) and the standard error (SE) were calculated and analyzed by using the generic inverse variance. The pooled HR of DFS or OS was chosen as the effect index. The included studies were divided into two subgroups, the MP component subgroup and the MP predominant subgroup, according to the proportion of the MP pattern. The effect of the MP pattern on DFS and OS in patients with lung ADC was analysed. The heterogeneity between the included studies was assessed using the Cochrane Q test and I^2 value [16]. If P>0.1 or I^2<50%, the heterogeneity was considered to be non-significant, and the fixed effects model was used; otherwise, the random effects model was used [16]. Begg's funnel plot and Egger's linear regression test were used to assess the publishing bias. All P values were two-sided, and P<0.05 was considered statistically significant.

Results
Study characteristics
A total of 227 potentially relevant studies were retrieved from the MEDLINE, EMBASE, and Cochrane databases. The screening process for available studies is shown in Fig. 1. Finally, 10 studies published from 2014 to 2018, which included a total of 4934 patients, were included in this meta-analysis. All included studies were retrospective; 2 of them came from Japan, 2 from South Korea, 4 from China, 1 from Germany and 1 from Australia. Five studies described the effect of the presence of an MP component on prognosis, and 5 studies described the effects of the MP predominant subtype on prognosis. DFS was used as a single prognostic indicator in 5 studies, 2 studies described both DFS and OS, and the remaining 3 studies only described OS. The HR and 95% CI in each study were obtained through multivariate Cox regression analysis, and then the pooled HR of the meta-analysis was calculated. The characteristics of the included studies are summarized in Table 1. The quality evaluation results of the included studies are shown in Table S1.

Effects of the MP pattern on DFS after lung ADC resection
Four of the five studies in the subgroup with the presence of an MP component reported the HR of DFS obtained by multivariate Cox analysis from 903 patients. The fixed effects meta-analysis showed that the DFS of MP component-positive patients was significantly worse than that of MP component-negative patients (HR 1.80, 95% CI 1.14–2.85, I^2 = 0%, P = 0.01) (Fig. 2).

Three of the five studies in the subgroup of the MP predominant subtype reported the HR of DFS obtained by multivariate Cox analysis from 1315 patients. The
Table 1 The characteristics of the included studies

| First Author (year) | Study Region | Starting and Ending Year | MP Pattern Definition | Total Number of Patients | Number of MP Patients | Age | TNM Staging Distribution | Surgical Approach | Median Follow-up Time | Outcome |
|---------------------|--------------|---------------------------|-----------------------|--------------------------|-----------------------|-----|---------------------------|-----------------|---------------------|---------|
| Liu (2014) [17]     | China        | 2007.5–2012.2             | MP component          | 248                      | 79                    | 60 (24–81) | 110 30 81 27             | Lobectomy       | 110                 | OS      |
| Tsubokawa (2016) [18]| Japan        | 2006.4–2010.12            | MP component          | 347                      | 49                    | unclear  | 325 11 11 192 155        | Limited Resection | 40.6                | DFS    |
| Moon (2016) [19]    | Korea        | 2010.1–2014.12            | MP component          | 168                      | 37                    | unclear  | 133 35 163               | Pneumonectomy    | 3                   | 29.1 (0.4–62.2) DFS |
| Yao (2016) [14]     | China        | 2012.9–2014.2             | MP component          | 20                       | 5                     | 62 (43–80) | 7 8 5 17 3              | Bilobectomy      | 30 (24–41) DFS   |
| Yi (2018) [13]      | Korea        | 2009–2012                 | MP component          | 368                      | 141                   | 62.6 (30–91) | 368 250 114 1           | DFS             |
| Westaway (2013) [20]| Australia    | 2000–2010                 | MP predominant        | 152                      | 8                     | 68 (31–100) | 79 42 31 133 8 11       |                | 43 (0–739) DFS |
| Sun (2014) [21]     | China        | 2002.1–2011.12            | MP predominant        | 136                      | 22                    | 57.6 (34–79) | 136 119                  |                | 74 (21–149) DFS, OS |
| Warth (2015) [22]   | Germany      | 2002–2010                 | MP predominant        | 674                      | 53                    | 626       | 264 145 22 549 22 87   |                | 38.2 DFS |
| Watanabe (2015) [8] | Japan        | 1998–2007                 | MP predominant        | 2316                     | 139                   | unclear | I + II 1912 III + IV 404 |                | OS |
| Zhang(2016) [9]     | China        | 2007.1–2010.6             | MP predominant        | 505                      | 49                    | 57 (24–83) | 221 81 203 443 19 11 |                | 32 43 (229–57.5) DFS, OS |

MP pattern definition: Semiquantitative record various patterns that may be present in 5% increments, the presence of MP component is defined as the proportion of MP pattern > 5%, and the MP predominant subtype defined as the MP pattern present in the largest proportion [3, 4]
fixed effects meta-analysis showed that the DFS of MP predominant subtype patients was also significantly worse than that of MP nondominant subtype patients (HR 1.62, 95% CI 1.20–2.21, $I^2 = 0\%$, $P = 0.002$) (Fig. 2).

Effects of the MP pattern on OS after lung ADC resection
One of the five studies in the subgroup with the presence of an MP component reported the HR of OS observed from 248 patients. The OS of MP component-positive patients was significantly worse than that of MP component-negative patients (HR 2.26, 95% CI 1.46–3.52, $P = 0.0003$) (Fig. 3).

Four of the five studies in the subgroup of the MP predominant subtype reported the HR of OS obtained by multivariate Cox analysis from 3109 patients. The fixed effects meta-analysis showed that the OS of MP predominant subtype patients was also significantly worse than that of MP nondominant subtype patients (HR 1.53, 95% CI 1.19–1.96, $I^2 = 9\%$, $P = 0.0009$) (Fig. 3).

**Publication bias**
Publication bias was evaluated by Begg’s funnel plot and Egger’s linear regression test. There was no publication bias among the 7 studies describing DFS ($P =
Discussion

Our meta-analysis of 10 studies (including 4934 patients) showed that both the presence of an MP component and the MP predominant subtype of lung ADC predicted worse DFS and OS after surgery. Lung ADC is divided into five major histological subtypes (lepidic, acinar, papillary, solid, and MP) according to the recommendation proposed by IASLC/ATS/ERS in 2011 [3]. These five major histological subtypes represent different aggressiveness characteristics [4]. Subsequent studies confirmed the predictive value of the new classification for prognosis and defined three subgroups: low-risk group (lepidic), intermediate-risk group (acinar and papillary) and high-risk group (solid and MP) [23–25]. Several studies in recent years have suggested that the MP predominant subtype predicts a poor prognosis for lung ADC [5–7]. Some studies agree on the adverse effects of the MP predominant subtype on DFS after lung ADC resection [9, 21, 22]. However, the effects of the MP predominant subtype on OS after lung ADC resection were not significantly different in the studies of Westaway et al. [20] and Sun et al. [21], although the HRs were >1. The reason for the lack of statistical significance might be that the sample number was relatively small, as there were only 8 and 22 MP-predominant subtype patients in the studies of Westaway et al. and Sun et al., respectively. Our results showed that in the MP predominant subgroup of 5 studies (including 271 patients with the MP predominant subtype), the pooled HRs of DFS and OS were 1.62 (95% CI 1.20–2.21) and 1.53 (95% CI 1.19–1.96), respectively.

In the subgroup with presence of an MP component, the pooled HRs of DFS and OS from 5 studies (including 311 MP-positive patients) were 1.80 (95% CI 1.14–2.85) and 2.26 (95% CI 1.46–3.52), respectively. Although the study of Yi et al. showed that the presence of an MP component could not predict the risk of recurrence after resection of lung ADC (HR 1.0, 95% CI 0.41–2.65, \( P = 0.919 \)) [14], all the included patients were in stage I without lymph node involvement, and their conclusion might not be applicable to all patients with MP patterns. Recent studies showed that patients with an MP component had significantly higher rates of occult lymph node metastasis than patients without an MP component [10–12]. Two other studies confirmed that the presence of an MP component was closely related to lymph node metastasis [26, 27]. Combining these findings with the clear impact of TNM staging on prognosis after lung ADC resection further supported our results.

This is the first meta-analysis evaluating the impact of the MP pattern on the prognosis of lung ADC according to two subgroups: the MP component subgroup and the MP predominant subgroup. The heterogeneity was not obvious in all subgroup analyses (I²<50%, \( P >0.1 \)). The summary data show that both patients with an MP component and patients with the MP predominant subtype have a higher probability of recurrence and worse overall survival. Current guidelines recommend adjuvant chemotherapy for patients whose TNM staging is higher than IIB after complete resection; stage IB and IIA patients with high risk factors may benefit from adjuvant chemotherapy after complete resection, especially patients with poorly differentiated tumours, vascular invasion, tumours with a diameter >4 cm and visceral pleural invasion [28, 29]. According to the guidelines published by the Chinese Medical Association, adjuvant chemotherapy can also be considered for stage IB lung ADC patients whose pathological subtypes are solid or MP after complete resection [29]. Several recent studies have also reported that stage IB patients with MP subtype lung ADC can benefit from adjuvant chemotherapy [30–32]. Our meta-analysis results provide further evidence that lung ADC patients with an MP component may potentially benefit from adjuvant chemotherapy after complete surgical resection due to their higher relapse rates and poorer survival outcomes. However, this conclusion needs to be further confirmed in large prospective studies.

Our meta-analysis has some limitations: First, all the included studies were retrospective, and some of the research subjects’ biases were uncontrollable. Propensity score matching was not used to eliminate the influence of confounding factors on the observation results. Second, our meta-analysis only included some studies that defined the presence of an MP component as a proportion of the MP pattern >5%. However, the prognosis of the part of lung ADC patients with MP pattern accounted for 1 to 5% after surgical resection has not been evaluated.

Conclusion

Both the presence of an MP component and the MP predominant subtype are related to poor DFS and OS after lung ADC resection and represent adverse prognostic factors for lung ADC patients. However, there are some limitations in this meta-analysis, and quantitative stratification based on the proportion of the MP component is needed to explore its effect on the prognosis of lung ADC patients in the future.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13019-020-01199-8.
Abbreviations
MP: Micro papillary; ADC: Adenocarcinoma; DFS: Disease-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; IASLC/ATS/ERS: The International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society; STAS: Spread through air spaces; QUIPS: Quality In Prognosis Studies; TNM: Tumor node metastasis; SE: Standard error.

Acknowledgements
Not applicable.

Authors’ contributions
WW put forward the idea and designed the research; All authors contributed to literature searching, data extraction and analysis; WW wrote the manuscript; LY revised the manuscript; The authors approved the final version of the manuscript.

Funding
This research is supported by the following funds: the National Natural Science Foundation of China (No.31860325); the High-level Health and Family Planning Technical Personnel Training Project of Yunnan Province (No. 2017006); the National Key Research and Development Plan for Precision Medicine (No. 2017FY090702).

Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, No. 519 Kunzhuo Road, Xishan District, Kunming City, Yunnan Province, China. 2Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.

Received: 6 March 2020 Accepted: 22 June 2020
Published online: 29 June 2020

References
1. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018; 68(4):425–45.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8(3):381–5.
5. Yoshida T, Mima T, Tsutani Y, Tsubokawa N, Sasada S, Miyata Y, et al. Prognostic role of subtype classification in small-sized pathologic N0 invasive lung adenocarcinoma. Ann Thorac Surg. 2016;102(5):1668–73.
6. Luo J, Huang Q, Wang R, Han B, Zhang J, Zhao H, et al. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. J Cancer Res Clin Oncol. 2016;142(9):2031–40.
7. Zhao X, Zhang Y, Qian K, Zhao L, Wang W, Teng LH. Prognostic significance of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage I lung adenocarcinoma: a retrospective study based on analysis of 110 Chinese patients. Thorac Cancer. 2017;8(6):565–71.
8. Watanabe Y, Kusumoto M, Yoshida A, Suzuki K, Asamura H, Tsuta K. Surgically resected solitary cavity lung adenocarcinoma: association between clinical, pathologic, and radiologic findings and prognosis. Ann Thorac Surg. 2015;99(3):968–74.
9. Zhang H, Lu C, Lu Y, Yu B, Lv F, Zhu Z. The predictive and prognostic values of factors associated with visceral pleural involvement in resected lung adenocarcinomas. Onco Targets Ther. 2016;9:2337–48.
10. Zhang J, Jing W, Li B, Guo H. Analysis of prognosis of pulmonary adenocarcinoma with a micropapillary pattern and its influencing factors. Cancer Res Clin. 2019;31(3):154–7.
11. Lee JS, Kim EK, Kim M, Shim H.S. Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces. Lung Cancer. 2018;123:121–6.
12. Dai C, Xie H, Kadeer X, Su H, Xie D, Ren Y, et al. Relationship of lymph node micrometastasis and micropapillary component and their joint influence on prognosis of patients with stage I lung adenocarcinoma. Am J Surg Pathol. 2017;41(9):1212–20.
13. Yao S, Zhi X, Wang R, Qian K, Hu M, Zhang Y. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Thorac Cancer. 2016;7(5):543–8.
14. Yi E, Bae MK, Cho S, Chung JH, Jheon S, Kim K. Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANJ J Surg. 2018;88(4):327–31.
15. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
17. Chao L, Yi-Sheng H, Yu C, Li-Xu Y, Xin-Lan L, Dong-Lan L, et al. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients. Lung Cancer. 2014;86(2):164–9.
18. Tsubokawa N, Mima T, Sasada S, Yoshiya T, Mimura T, Murakami S, et al. Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma. Eur J Cardiothorac Surg. 2016;49(1):293–9.
19. Moon T, Sung SW, Lee KY, Park JK. Clinicopathological characteristics and prognosis of non-lepidermal invasive adenocarcinoma presenting as ground glass opacity nodule. J Thorac Dis. 2016;8(9):2562–70.
20. Westaway DD, Toon CW, Farzin M, Sisom L, Watson N, Brady PW, et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013;45(6):553–8.
21. Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014;12:148.
22. Warth A, Muley T, Kossakowski C, Stenzinger A, Diermaen H, et al. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol. 2015;10(4):638–44.
23. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—based on a hospital study in China. Eur J Surg Oncol. 2013;39(1):1262–8.
24. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30(13):1438–46.
25. Hu HD, Wan MY, Xu CH, Zhan P, Zou J, Zhang QQ, et al. Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance. J Thorac Dis. 2013;5(6):841–6.
26. Song CY, Kunitama D, Sakai T, Tsuchima T, Fukuda I. Novel approach for predicting occult lymph node metastasis in peripheral clinical stage I lung adenocarcinoma. J Thorac Dis. 2019;11(4):1410–20.
27. Yeh YC, Kadota K, Natajori J, Sima CS, Rizk NP, Jones DR, et al. International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification predicts occult lymph node metastasis in stage I lung adenocarcinoma: a meta-regression analysis. J Thorac Oncol. 2016;11(5):648–57.
metastasis in clinically mediastinal node-negative lung adenocarcinoma. Eur J Cardiothorac Surg. 2016;49(1):e9–e15.

28. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.

29. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–72.

30. Hung JJ, Wu YC, Chou TY, Jeng WJ, Yeh YC, Hsu WH. Adjuvant chemotherapy improves the probability of freedom from recurrence in patients with resected stage IIB lung adenocarcinoma. Ann Thorac Surg. 2016;101(4):1346–53.

31. Qian F, Yang W, Wang R, Xu J, Wang S, Zhang Y, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IIB lung adenocarcinoma. J Thorac Cardiovasc Surg. 2018;155(3):1227–35.e2.

32. Ma M, She Y, Ren Y, Dai C, Zhang L, Xie H, et al. Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IIB lung adenocarcinoma. J Thorac Dis. 2018;10(9):5384–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.